What do labels and trials say about testosterone isocaproate dosage?
60 mg of Testosterone Isocaproate at 60 mg/mL is 1 mL, the 100 mark on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Concentration | Draw per dose |
|---|---|
| 60 mg/mL | 60 mg/mL: 30 mg is 0.5 mL, the 50 mark, 60 mg is 1 mL, the 100 mark |
The UK label for Sustanon 250, a four-ester mix with 60 mg testosterone isocaproate in each 1 ml ampoule, says one injection of 1ml per 3 weeks is usually adequate for adults, adjusted to the individual patient's response.1
How the oil is supplied and measured
Isocaproate is one of four esters in Sustanon 250: the UK label gives each 1 ml ampoule as 30 mg testosterone propionate, 60 mg phenylpropionate, 60 mg isocaproate and 100 mg decanoate, 176 mg of testosterone in total, and the New Zealand data sheet gives the same in an ampoule or vial, though it says the vials are currently not available.12 A search of DailyMed, ClinicalTrials.gov and PubMed turned up no single-ingredient isocaproate product. The label's 250mg/ml is all four esters together; only 60 mg of each 1 ml is isocaproate, so 60 mg of isocaproate is 1 ml of the mix, or 100 units on a U-100 syringe.1
60 mg of Testosterone Isocaproate at 60 mg/mL is 1 mL, the 100 mark on a U-100 syringe.
What the labels say about dose and schedule
The UK label gives the adult interval in weeks, not days: for adults (incl. elderly) it says one injection of 1ml per 3 weeks is usually adequate, with the dose in general adjusted to the response of the individual patient, and its indication is testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.1 The New Zealand data sheet gives the same 1 mL per three weeks.2 The UK label gives deep intramuscular injection and warns that, as with all oily solutions, Sustanon 250 must be injected strictly intramuscularly and very slowly; it names no injection site.1 No label gives a dose for isocaproate alone.
For female-to-male transsexual supportive therapy, the UK label says specialist centres have used doses from 1 mL every two weeks to 1 mL every four weeks.1 It warns that treatment may induce signs of virilisation in women.1
Doses in human studies
A search of the trial registry and PubMed turned up no human trial of isocaproate alone, and the Kocaman 2026 cohort of 34 people in the table below names only mixed testosterone esters.3 No label or trial defines a cycle for isocaproate; the Büyükgebiz 1995 trial in thirteen boys gave 4 doses at 3-week intervals, and the NCT05166083 record (26 trans men) lists 8 doses once per 21 days.45
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Büyükgebiz, 19954 | Intramuscular 200 mg testosterone as propionate, phenylpropionate and isocaproate esters, 4 times at 3-week intervals | Thirteen boys with constitutional delayed puberty | 2 years follow-up |
| NCT01454011 record, phase 4, non-randomised, 2008 to 20116 | Sustanon 250 (30 mg propionate, 60 mg phenylpropionate, 60 mg isocaproate, 100 mg decanoate) injected in 3 weeks intervals, against a testosterone 50mg transdermal gel arm | 140 enrolled | Primary outcome at 6 months |
| Solheim et al., 2020, randomised, double-blind7 | Intramuscular 250 mg Sustanon (four esters) or placebo on days 0 and 21 | Nineteen eugonadal men | Samples on days 1, 3, 5, 10 and 14 after injections |
| Kocaman et al., 2026, prospective cohort3 | Intramuscular mixed esters (isocaproate not named): 125 mg every 21 days for 3 months, then escalation; or 250 mg every 21 days | 34 people assigned female at birth | 6-month follow-up |
| NCT05166083 record, observational cohort, 2022 to 20255 | Testosterone isocaproate, volume given as '... ml', 8 doses, once per 21 days | 26 trans men enrolled | Target duration 8 months |
| Bui et al., 20138 | Intramuscular testosterone-ester mixture (isocaproate not named): 125 mg/2 weeks or 250 mg/4 weeks | Female-to-male transgender adolescents from age 16 | 250 mg/4 weeks gave values below the reference range at the end of the 4 weeks |
| Katz et al., 19939 | Intramuscular testosterone propionate 15 mg, phenylpropionate 30 mg, isocaproate 30 mg and decanoate 50 mg | 21 male and 11 female patients with beta thalassaemia major | Intramuscular testosterone peaked seven days after injection |
Storage
The UK label gives storage before use as below 30°C, not refrigerated or frozen, in the original package away from light, with a shelf life of 5 years.1 It says an ampoule cannot be resealed once open in a way that keeps its contents sterile, so the solution is to be used immediately, and that a vial, a form it lists as currently not available, is single use in one patient only.2 Beyond the immediate use of an ampoule once open and the single use of a vial, the labels give no storage after opening, and no stability data for a drawn-up or multi-dose vial turned up.
Frequently asked questions
What is the half-life of testosterone isocaproate?
What are the label contraindications?
The New Zealand data sheet contraindicates it in peanut or soya allergy, pregnancy, known or suspected prostate or breast cancer, breastfeeding and, as it contains benzyl alcohol, children under 3 years of age.2
References
- EMC (UK). Sustanon 250, 250mg/ml solution for injection - Summary of Product Characteristics (SmPC) - (emc) | 5373. medicines.org.uk
- Medsafe NZ. SUSTANON. medsafe.govt.nz
- PubMed. Prospective evaluation of testosterone dose strategy in transgender individuals assigned female at birth: hormonal equivalence and psychological and behavioral outcomes. 2026. pubmed.ncbi.nlm.nih.gov
- PubMed. Treatment of constitutional delayed puberty with a combination of testosterone esters. 1995. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT05166083: Investigation of the Perceptual and Acoustic Voice in Trans Man. 2025. clinicaltrials.gov
- ClinicalTrials.gov. NCT01454011: The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups. 2011. clinicaltrials.gov
- PubMed. Changes in blood parameters after intramuscular testosterone ester injections - Implications for anti-doping. 2020. pubmed.ncbi.nlm.nih.gov
- PubMed. Salivary testosterone in female-to-male transgender adolescents during treatment with intra-muscular injectable testosterone esters. 2013. pubmed.ncbi.nlm.nih.gov
- PubMed. Pharmacokinetics of sex steroids in patients with beta thalassaemia major. 1993. pubmed.ncbi.nlm.nih.gov